Breaking News
Menelas Pangalos
About Menelas Pangalos
I’m a lifelong scientist and pharmaceutical executive at AstraZeneca where we are led by science, driven by patients and are constantly pushing the boundaries of what science can do to deliver life-changing medicines to the people who need them most.
Being able to create ground-breaking medicines has always excited me. The rate of change we are seeing across healthcare is more rapid than ever before and is opening up incredibly exciting opportunities not thought possible just a few years ago.
Incredible technological advances are enabling us to increase our understanding of disease biology at a molecular level and discover what is driving many of our most complex diseases. The more knowledge we gain, the better we can predict the clinical success of our candidate drug molecules, accelerating their delivery to get the right treatments to the right patients.
I am passionate about taking basic research and translating that understanding into the discovery and delivery of medicines that could transform the lives of patients. We are constantly learning from the people who live with the diseases our medicines treat.
It is vital we understand their needs so we can make sure that any great science in the lab can make a real difference to their lives.
All of this requires exceptional talent and remarkable teamwork which is why we have created a rich and diverse R&D culture which inspires people with curious minds to work free from fear of failure, free to ask the right questions and make bold decisions.
We work side-by-side with partners, not just from within our industry but across academia, biotech, governments and scientific organisations to share ideas and collaborate because the next generation of therapeutics needs the next generation of minds as we look to extend the possible and help shape the future of healthcare.
Vaxzevria Approved in the EU as Third Dose Booster Against COVID-19
May 23 2022
AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the […]
Farxiga Met Primary Endpoint in DELIVER Phase III Trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients with Preserved Ejection Fraction
May 6 2022
High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically […]
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
January 17 2022
BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration […]
Vaxzevria Significantly Boosted Antibody Levels Against Omicron
December 23 2021
AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a […]
Evusheld Long-acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Independent FDA Study
December 17 2021
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralising […]
Evusheld (Formerly AZD7442) Long-acting Antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19
December 9 2021
AstraZeneca‘s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the […]
AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial
October 11 2021
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca‘s AZD7442, a […]
VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform
September 23 2021
VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) […]
Forxiga Approved in the EU for the Treatment of Chronic Kidney Disease in Patients With and Without Type-2 Diabetes
August 9 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) […]
Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern
July 23 2021
Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of […]
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
July 8 2021
AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for […]